Zevra Therapeutics
ZVRA
31 hedge funds and large institutions have $21.7M invested in Zevra Therapeutics in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
19% more funds holding
Funds holding: 26 → 31 (+5)
11% more capital invested
Capital invested by funds: $19.5M → $21.7M (+$2.16M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
Top Sellers
| 1 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$68.2K |
| 2 |
VF
Virtu Financial
New York
|
-$53K |
| 3 |
Morgan Stanley
New York
|
-$17.1K |
| 4 |
ISB
Iowa State Bank
Urbandale,
Iowa
|
-$15.1K |
| 5 |
SIM
Spark Investment Management
New York
|
-$14.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $3K | -$8.99K | -149 | -79% |
|
27
Macquarie Group
Sydney, NSW 2000,
Australia
| $2K | +$2.29K | +38 | New |
|
|
VF
28
Virtu Financial
New York
| – | -$53K | -903 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$9K | -153 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | +$422 | +7 | New |
|
31
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$483 | +8 | New |
|
|
SWP
32
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$483 | +8 | New |
|
ZVRA Hedge Fund Activity: Q4 2017 in Review
31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2017, worth a combined $21.7M — up 11% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ZVRA positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $146K. The largest seller was Arete Wealth Advisors, cutting an estimated $68.2K.
- 31 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2017, up from 26 in Q3 2017.
- Funds reported $21.7M of Zevra Therapeutics stock for Q4 2017, up 11% quarter-over-quarter.
- 7 funds opened new Zevra Therapeutics positions in Q4 2017 and 2 closed out, a net change of +5 holders.
- The largest Zevra Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $146K added.
- The largest Zevra Therapeutics seller in Q4 2017 was Arete Wealth Advisors, an estimated $68.2K sold.
Based on aggregated 13F filings for Q4 2017.